熱門資訊> 正文
礼来公司（Eli Lilly）获得因卢尼司群（imlunestrant）治疗乳腺癌的批准
2025-09-26 03:21
- The U.S. FDA has approved Eli Lilly's (NYSE:LLY) imlunestrant, under the brand name Inluriyo, as a second-line therapy for ER+, HER2–, and ESR1-mutated advanced or metastatic breast cancer.
- The oral estrogen receptor antagonist won approval based on results from the phase 3 EMBER-3 trial which found that Inluriyo cut the risk of progression or death by 38% compared to endocrine therapy.
- In patients with ESR1-mutated breast cancer, those on Inluriyo had a median progression-free survival of 5.5 months vs. 3.8 months with fulvestrant or exemestane.
- Inluriyo is in another phase 3 trial examining the treatment in an adjuvant setting for individuals with ER+, HER2– early breast cancer.
More on Eli Lilly
- Eli Lilly and Company (LLY) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
- Eli Lilly: Buying The Dip With Confidence
- Eli Lilly: Orforglipron Sets Path Of Continued Revenue Growth In T2D And Obesity
- Eli Lilly ends trial of drug to stop muscle wasting with weight loss med Zepbound
- Lilly plans to launch experimental weight-loss pill in India - report
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
